- 1 **Title**: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm
- 2 Development and Rupture: Insights from Genetic and Experimental Models
- 4 **Author:** Yaozhong Liu¹, Huilun Wang^{1,2}, Minzhi Yu³, Lei Cai⁴, Ying Zhao¹, Yalun
- 5 Cheng¹, Yongjie Deng¹, Yang Zhao¹, Haocheng Lu⁵, Xiaokang Wu¹, Guizhen Zhao^{1,6},
- 6 Chao Xue^{1,7}, Hongyu Liu¹, Ida Surakka¹, Anna Schwendeman³, Hong S. Lu⁴, Alan
- Daugherty⁴, Lin Chang¹, Jifeng Zhang¹, Ryan E. Temel^{4,*}, Y. Eugene Chen^{1,8,*}, Yanhong
- 8 Guo^{1,*}

9

- 10 ¹Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan
- 11 Medical Center, Ann Arbor, Michigan, USA.
- 12 ²Department of Molecular Physiology and Biological Physics, University of Virginia
- 13 School of Medicine, Charlottesville, Virginia, USA.
- ³Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
- ⁴Saha Cardiovascular Research Center and Department of Physiology, College of
- 16 Medicine, University of Kentucky, Lexington, Kentucky 40536.
- 17 ⁵Department of Pharmacology, Southern University of Science and Technology,
- 18 Guangdong, China.
- 19 ⁶College of Pharmacy Health, University of Houston, Houston, Texas, USA.
- ⁷Department of Internal Medicine, Rochester General Hospital, Rochester, New York,
- 21 USA.

24

- ⁸Center for Advanced Models for Translational Sciences and Therapeutics, University of
- 23 Michigan Medical Center, Ann Arbor, Michigan, USA.
- 25 Total word count: 8255
- 27 * To whom correspondence should be addressed:
- 28 Yanhong Guo, M.D., Ph.D., Department of Internal Medicine, University of Michigan
- 29 Medical Center, Ann Arbor, MI 48109, Phone: 734-764-1405, Email:
- 30 yanhongg@umich.edu
- 31 Or

- 32 Y. Eugene Chen, M.D., Ph.D., Department of Internal Medicine, University of Michigan
- 33 Medical Center, Ann Arbor, MI 48109, USA. Phone: 734-936-9548, Email:
- 34 echenum@umich.edu
- 35 Or

- 36 Ryan E. Temel, Ph.D., Saha Cardiovascular Research Center and Department of
- Physiology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
- 38 Phone: 859-218-1706, Email: ryan.temel@uky.edu

Abstract:

 Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medications. This study integrated genetic, proteomic, and metabolomic data to identify causation between increased triglyceride (TG)-rich lipoproteins and AAA risk. Three hypertriglyceridemia mouse models were employed to test the hypothesis that increased plasma TG concentrations accelerate AAA development and rupture. In the angiotensin II-infusion AAA model, most *LpI*-deficient mice with severely high plasma TG concentrations died of aortic rupture. Consistently, *Apoa5*-deficient mice with moderately increased TG concentrations had accelerated AAA development, while human *APOC3* transgenic mice with dramatically increased TG concentrations exhibited aortic dissection and rupture. Increased TG concentrations and palmitate inhibited lysyl oxidase maturation. Administration of antisense oligonucleotide targeting *Angptl3* profoundly inhibited AAA progression in human *APOC3* transgenic mice and *Apoe*-deficient mice. These results indicate that hypertriglyceridemia is a key contributor to AAA pathogenesis, highlighting the importance of triglyceride-rich lipoprotein management in treating AAA.

Introduction

Abdominal aortic aneurysm (AAA) is a progressive vascular disease characterized by the localized enlargement of the abdominal aorta. The prevalence of AAA is estimated to be as high as 8% in men and 2% in women over 65 years of age.¹ Most AAAs are asymptomatic, but the mortality rate is up to 80% if rupture occurs.² As maximum aortic diameter is the most established predictor of aneurysm rupture, current guidelines recommend considering surgical repair for asymptomatic AAA patients when maximal aortic diameter is ≥ 50 mm in women and ≥ 55 mm in men. Open surgical or percutaneous endovascular aneurysm repair is still the only therapeutic option.³ Patients with AAA smaller than these thresholds are typically monitored through imaging surveillance. AAA-relevant risk factors, including smoking, male sex, aging, hypertension, and hyperlipidemia, are associated with enhanced aneurysm formation and growth. Currently, medications to reduce AAA risk factors, such as angiotensin II (AngII) receptor antagonists, beta-adrenoceptor blockers, statins, and anticoagulants, have not been proven effective in halting the growth of an aneurysm or preventing the rupture of asymptomatic AAA based on the findings from randomized controlled trials.⁴4.5

Our recent comprehensive genome-wide association studies (GWAS) meta-analysis, which included approximately 40,000 individuals with AAAs and over 1 million individuals without AAAs, has demonstrated that one-third of the lead variants at the 121 genome-wide significant AAA risk loci are associated with major lipid fractions, such as total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), or high-density lipoprotein cholesterol (HDL-C).⁶ Other genetic association studies have identified that a 1-standard deviation increase in TG concentrations is associated with a 69% higher risk of AAA.^{7,8} Population-based studies have reported that individuals with increased serum very low-density lipoprotein-cholesterol (VLDL-C) and TG concentrations are more likely to develop larger AAA sizes and have a higher risk of rupture.^{9,10} These epidemiologic and genetic findings suggest that increased TG-rich lipoproteins (TRL) may accelerate AAA development and rupture, and modulating TG concentrations or metabolites may become new therapeutic strategies for AAA.

TG, also known as triacylglycerols (TAG), are composed of glycerol and fatty acids and are the most abundant lipids in the body. Chylomicrons transport dietary triglycerides from the small intestines, and VLDLs transport endogenously synthesized triglycerides from the liver to peripheral tissues, such as the heart, skeletal muscle, and adipose tissues. Triglyceride metabolism is a complex process involving the breakdown and utilization of this lipid. Several proteins and enzymes play critical roles in regulating triglyceride metabolism.¹¹ Among these, lipoprotein lipase (LPL), ApoC-III

(apolipoprotein C-III, APOC3), ApoC-II, ApoA-V (apolipoprotein A5, APOA5), and angiopoietin-like proteins (ANGPTL3, ANGPTL4, and ANGPTL8) are key players. LPL is a critical enzyme that facilitates the hydrolysis of triglycerides carried by chylomicrons and VLDL into free fatty acids (FFA) and glycerol, allowing them to be utilized by various cells for energy or storage. Our previous study found that an intronic LPL variant, associated with increased LPL expression, was strongly related to reduced plasma TG concentrations and AAA risk.⁶ APOA5 is almost exclusively expressed in the liver and secreted in conjunction with VLDL particles. ApoC-III is a constituent of chylomicrons and VLDL particles and inhibits LPL activity, while ApoA-V and ApoC-II enhance LPL activity and promote the clearance of TG-rich lipoproteins. ANGPTL3 and ANGPTL8 are secreted proteins and inhibitors of LPL-mediated plasma TG clearance. In numerous studies involving humans and animals, loss-of-function of APOC2 or APOA5 is associated with increased plasma concentrations of TG and chylomicronemia. 12,13 Among the putatively causal circulating proteins associated with AAA, we observed that higher APOA5 expression is associated with decreased AAA risk.⁶ Conversely, gene silencing of APOC3 or ANGPTL3 significantly reduced TG and TC concentrations. making this method an effective strategy for lowering plasma lipids and preventing cardiovascular diseases. 14-17 In the present study, we demonstrated that increased TGrich lipoproteins accelerate AAA formation and rupture, and we provide evidence that effective management of plasma TG concentrations can alleviate AAA progression.

Methods

96

97 98

99 100

101

102

103 104

105

106 107

108

109

110 111

112

113

114

115 116 117

118

119

120

121 122

123

124 125

126

127

128

129

130 131

132

A detailed description of the methods is available in the Supplemental Materials. All animal procedures followed the protocols approved by the Institutional Animal Care & Use Committee (IACUC) at the University of Michigan and University of Kentucky.

Statistic analysis

- Analyses of RNA sequencing and genetic data were performed using R language (v4.3.0). Statistical analyses of other data were conducted using GraphPad Prism 10. Most of the data are presented as mean ± standard error of the mean (SEM). The distribution of data was assessed using the Kolmogorov-Smirnov test (for n > 4) or the Shapiro-Wilk test (for $n \le 4$). For normally distributed data, Student's t-tests were used to compare two groups, one-way analysis of variance (ANOVA) was used to compare multiple groups, and the Sidak method was applied for multiple comparison correction. For non-normally distributed data, Mann-Whitney U tests were used to compare two groups, Kruskal-Wallis tests were employed to compare multiple groups, and the Dunn method was used for multiple comparisons correction. A P-value less than 0.05 was
- 133 considered statistically significant.

Results

134

167

168

169

170

171

Genetic, proteomic, and metabolic studies underscore high triglyceride-rich 135 136 lipoproteins as a causal risk factor for AAA. 137 Genetic variants that modulate the expression of genes encoding the candidate proteins 138 or the abundances of metabolites represent valuable tools for guiding therapeutic 139 strategies. Recent studies have identified cis-acting protein quantitative trait loci (cispQTL) that can be used as instrumental variables (IVs) for inferring causality. 18,19 140 141 Combining cis-pQTL and GWAS findings, we performed Mendelian randomization (MR) 142 analyses to assess the causal effects of circulating proteins on AAA risk and identified 143 that 41 out of 2,698 circulating proteins were significantly associated with AAA after 144 adjusting for multiple tests (Fig 1, full MR results in Supplementary Table 1). Among 145 them, genetically determined circulating APOC3 (OR=1.84) and APOA5 (OR=0.61) had 146 the most significant effects on AAA risk. Seven of the 41 circulating proteins, including 147 APOC3, APOA5, LPL, APOE, PLTP (phospholipid transfer protein), PCSK9 (proprotein 148 convertase subtilisin/kexin type 9), and LPA (lipoprotein(A)), play an important role in 149 lipid metabolism, especially in VLDL and chylomicron metabolism (Fig 1B). Our previous 150 GWAS findings demonstrated that 42 lead variants at the AAA risk loci are associated with major lipid fractions. 6 After prioritizing the role of five major lipoprotein components 151 152 (HDL-C, LDL-C, TG, APOA1, and APOB) as risk factors for AAA, TG was the top-ranked 153 risk factor for AAA with a marginal inclusion probability of 0.81 (P=0.007; Supplementary Table 2). Consistent with previous studies, 6-8 LDL-C, HDL-C, and APOA1 were 154 significant factors (Supplementary Table 2). These genetic and proteomic findings 155 156 indicate that TG-related metabolism may play a substantial role in AAA pathogenesis. 157 158 To further identify genetic associations between AAA risk loci and circulating metabolic traits, we utilized the data from a recently published GWAS study of 233 circulating 159 metabolites to perform a two-sample MR analysis. 20 The NMR-measured metabolites 160 161 included 213 lipid traits (lipids, lipoproteins, and fatty acids) and 20 non-lipid traits (amino acids, ketone bodies, and glucose/glycolysis-related metabolites).²⁰ Lipoproteins 162 163 are classified by particle sizes (XXL, XL, L, M, S, and XS) and then subgrouped by the components (particle number, phospholipids, cholesterol, cholesterol ester, free 164 165 cholesterol, and TG). For each metabolite, we used the inverse variance-weighted 166 (IVW) method as the primary MR approach and MR-Egger analysis and weighted

findings (Fig 1C, full MR results in Supplementary Table 3).9,10,21,22 Interestingly, we

median-based regression methods as sensitivity analyses. We demonstrated that TG-

the components in TRL particles, were positively associated with AAA risk, while HDL

and glucose were negatively associated with AAA risk, consistent with population

rich lipoproteins, including VLDL, IDL (intermediate density lipoprotein), and LDL, and all

noticed that TG component of HDL was positively associated with AAA risk compared to other components in HDL particles, such as cholesterol and phospholipids (Fig 1C). Concomitantly, we observed that total fatty acid and saturated fatty acid, the metabolites of triglycerides, were also positively associated with AAA risk. These findings raise the possibility that lowering triglycerides and related metabolites could provide a therapeutic pathway for reducing the risk of AAA.

Impaired LPL activity accelerates AAA development and rupture.

172

173

174

175

176

177

178179

180

181

182

183 184

185

186 187

188

189

190

191

192

193194

195 196

197

198

199

200

201

202203

204

205

206

207

208

209

210

Chronic subcutaneous infusion of AngII serves as a well-established AAA model in mice under hypercholesterolemic conditions, which includes using mice with deficiencies in apolipoprotein E (Apoe) or LDL receptor (Ldlr) or manipulating by adeno-associated virus-mediated overexpression of *Pcsk9* to induce hyperlipidemia.²³⁻²⁵ Our previous GWAS demonstrated that LPL variants that lead to increased plasma TG concentrations were linked to an increased risk of AAA.6 The MR analysis also identified circulating LPL levels to be negatively associated with AAA risk (Fig 1B). To validate whether increased TG concentrations caused by impaired LPL activity can result in AAA development and rupture, we infused AnglI into male, inducible Lpl-deficient (iLpl-'-) mice fed a lowcholesterol Western diet. With AnglI infusion, an aortic rupture occurred in 94% (16/17, combined data from two cohorts of animal studies) of iLpf- mice compared to 9.5% (2/21, combined data from two cohorts of animal studies) aortic rupture rate in littermate control mice (Fig 2A-C, Supplementary Fig 1). The only survival iLpt^{-/-} mouse did not have AAA and had a plasma TG concentration of 474 mg/dL and TC concentration of 233 mg/dL. In contrast, after 1 week of Western diet feeding but before AnglI infusion, the majority of the iLpt^{-/-} mice had severely increased TG concentrations, which were as high as 11,103 mg/dL (4,077 \pm 3,218 mg/dL) compared to 66 \pm 28 mg/dL in Lpf^{f/f} mice (Supplementary Fig 1A). Saline infusion, as a control, did not cause aortic rupture in either genotype (Supplementary Fig 1C). These findings showed that severely increased TG concentrations as a consequence of LPL deficiency resulted in aortic rupture and death in the AnglI-induced AAA model.

Then, we employed other mouse strains with increased, but not severely elevated, TG concentrations to validate our hypothesis. We performed all the following AAA studies in mice fed a standard rodent laboratory diet to minimize the effects of hypercholesterolemia induced by a Western diet. ApoA-V is produced in the liver and secreted into circulation, where it exerts an important role in regulating plasma TG concentrations by enhancing LPL activity to hydrolyze triglycerides. Male *Apoa5*-deficient mice showed a 2-3-fold increase in TG concentrations but no difference in TC concentrations (Fig 2D-G), consistent with previous findings. AAAA was evaluated after a 4-week AnglI infusion. The hypertriglyceridemic *Apoa5*-deficient mice had increased

AAA incidence and larger maximal abdominal aorta diameter (Fig 2E, H, I). There was no difference in blood pressure before and after AngII infusion between *Apoa5*-deficient mice and their littermate controls (Fig 2J). This phenotype was not observed in *Apoa5*-deficient female mice, which had only slightly increased TG concentrations (Fig 2K-O). In addition, female mice demonstrate markedly lower incidences of AAA than males due to sex hormones or sex chromosomes.²⁶ These findings imply the causative roles of elevated TG concentrations in AAA pathogenesis.

Moderately to severely increased triglyceride levels accelerate AAA development and rupture in human *APOC3* transgenic mice.

Increased plasma ApoC-III concentrations are linked to enhanced production and slowed clearance of triglyceride-rich lipoproteins, causing hypertriglyceridemia. Human *APOC3* transgenic (h*APOC3* Tg) mice and age/sex-matched wild-type littermates were fed a standard rodent laboratory diet (Fig 3A). Compared with controls, male h*APOC3* Tg mice had about 7-fold increase in plasma TG concentrations (Fig 3B) and about 1-fold elevations in plasma TC concentrations (Fig 3C) and non-esterified fatty acids (NEFA, Fig 3D). We observed a low incidence of AAA in wild-type littermates (2 out of 17), similar to the literature.²⁶ However, there was a dramatically increased AAA incidence and a larger maximal diameter of the suprarenal aorta in h*APOC3* Tg mice (11 out of 13 surviving animals), as well as a higher dissection rate (8 out of 13 surviving animals) and another 2 mice dying from AAA rupture (Fig 3E-H). There was no difference in systolic blood pressure (SBP) between h*APOC3* Tg mice and controls (Fig 3I). A similar phenotype was observed in female mice (Fig 3J-O), indicating that dramatically increased TG concentrations accelerated AAA development, surpassing the protective effects of female hormones.

The effects of increased TG concentrations on AAA development were also evaluated in a PPE (porcine pancreatic elastase)-induced AAA model, in which AAA progression is independent of hypercholesterolemia. Based upon a 50% increase in the maximal abdominal aorta diameter as AAA on day 14 post-operative, the incidence of AAA was 100% for both male and female hAPOC3 Tg and littermate control mice (Supplementary Fig 2 and Supplementary Fig 3). Male hAPOC3 Tg mice showed significantly larger maximal aortic diameters than littermate controls, demonstrating that increased TG concentrations accelerated AAA growth (Supplementary Fig 2A-E). Even though female hAPOC3 Tg mice had lower TG concentrations than males (635 ± 36 mg/dL v.s. 946 ± 258 mg/dL, p = 0.0005), the increased TG concentrations in females were sufficient to cause larger aortic diameters (Supplementary Fig 3A-D).

These findings from the three hyperglyceridemia mouse models indicate that increased TG concentrations accelerate AAA rupture and aneurysm growth.

Palmitate and increased triglyceride concentrations inhibit lysyl oxidase maturation in human aortic smooth muscle cells and aortas.

249

250

251252

253

254

255

256

257258

259

260

261

262

263

264265

266267

268

269

270

271

272

273274

275

276

277

278

279

280

281

282

283

284 285

286

287

Supplementary Table 4).

The pathophysiology of AAA is intricately linked to the disruption of smooth muscle cell (SMC) homeostasis within the aortic wall, including phenotypic switching, cell death, extracellular matrix (ECM) remodeling, and inflammatory responses.²⁸ Serum from Apoa5-deficient or hAPOC3 Tg mice, as well as VLDL and HDL particles, did not affect primary human aortic smooth muscle cell (HASMC) viability (Supplementary Fig 4A-C), while incubation with LDL slightly increased cell numbers (Supplementary Fig 4C). The presence of APOA5 in the conditional medium did not regulate the expression of contractile markers in the presence of either Platelet-Derived Growth Factor-BB (PDGF-BB) or Transforming growth factor-beta (TGFβ) (data not shown), suggesting other mechanisms may exist. APOC3 overexpression caused elevated plasma TG concentrations accompanied by increased plasma NEFA concentrations (Fig 3D and Supplementary Fig 2C). Palmitic acid (PA) is the most common saturated fatty acid in the human body, typically accounting for 20–30% of the total fatty acids.²⁹ Bulk RNA sequencing (RNA-seg) analysis was performed to compare PA-incubated HASMC with BSA-treated (vehicle control) cells. Compared to the BSA-incubated group, PAincubated HASMC showed an apparent reduction in ECM assembly pathways, including collagen chain trimerization, elastic fiber formation and maturation, (Fig 4A-D), and increased expression of the inflammation-related gene (Supplementary Fig 5A-B,

TGF-β and lysyl oxidase (LOX) are crucial in regulating the cross-linking of collagen and elastin in the ECM. LOX was unexpectedly upregulated compared to the most downregulated genes in the elastic fiber formation and maturation pathways (Fig 4D). In primary HASMC, PA incubation induced the transcription of LOX, showing increased mRNA abundance by qRT-PCR (Fig 4E). LOX is initially synthesized as a preproprotein, which undergoes several post-translational modifications for its maturation and functional activation. Impairments in LOX activity, whether due to genetic mutations or LOX inhibitors, can lead to AAA formation and rupture. 30-32 Our RNA-seq data indicated that PA incubation downregulated the expression of BMP-1 (Bone morphogenetic protein 1), ADAMTS2 (a disintegrin and metalloproteinase with thrombospondin motif 2), and ADAMTS14, which are critical enzymes controlling LOX activation by the proteolytic removal of the propeptide region. We further confirmed that PA incubation downregulated BMP-1 and ADAMTS2 transcriptions in HASMCs (Fig 4F). Immunoblot

analyses demonstrated that incubation with TGF-β increased the abundance of the

mature form of LOX. However, the presence of PA blocked its effect, resulting in a less mature LOX (Fig 4G, I). LOX overexpression increased the mature form of LOX in HASMC, which was suppressed by incubation with PA (Fig 4H), indicating that PA interferes with the maturation process of LOX in HASMC. Nicotine, one of the wellestablished AAA risk factors, also repressed LOX maturation in HASMC (Supplementary Fig 6). These findings suggest that PA and nicotine may play a synergistic role in the pathogenesis of AAA by blocking LOX activation.

288

289 290

291

292

293

294

295 296

297

298

299 300

301

302

303

304

305

306

307

308

309 310

311

321

To investigate the effects of increased circulating palmitate concentrations on the maturation of LOX in aortas, we administered ethyl palmitate, which can be hydrolyzed to free palmitate in rodents.³³ The mature LOX abundance in suprarenal abdominal aortas was inhibited significantly after administration of ethyl palmitate compared to the vehicle or control intact aortas (Fig 4J). Then, we examined whether increased TG concentrations affected the maturation of LOX in the aortas of hAPOC3 Tg and littermate control mice. There was no difference in the abundance of matured LOX in suprarenal abdominal aortas between the two groups without AnglI infusion (Fig 4K). We observed a dramatic upregulation of mature LOX upon AnglI infusion in control mice (Fig 4K), suggesting a protective and compensatory mechanism to enhance elastic fiber assembly to protect against the effects of Angll. However, this response disappeared in hAPOC3 Tg mice (Fig 4K), indicating that increased TG and/or palmitate inhibited LOX maturation in the aortas, which may contribute to AAA development and rupture.

Anaptl3 ASO inhibits AAA formation and rupture in APOC3 Tg mice.

Based on the above findings, we asked whether lowering TG levels could attenuate 312 AAA formation and rupture. We administrated fenofibrate and niacin, commonly used for 313 treating hypertriglyceridemia, but only observed a 14-17 % reduction of plasma TG 314 concentrations in hAPOC3 Tg mice (Supplementary Fig 7). N-acetylgalactosamine (GalNAc)-conjugated antisense nucleotides (ASO) targeting of hepatocyte ANGPTL3 315 results in significantly decreased plasma TG concentrations in animals and 316 317 humans. 15,16,34 In hAPOC3 Tg mice, administration of Angptl3 ASO dramatically 318 suppressed hepatic Angpt/3 mRNA abundance by 64% and the plasma ANGPTL3 319 concentrations by 81% (Fig 5A-C). Consequently, administration of the Angpt/3 ASO 320 significantly reduced concentrations of NEFA, triglycerides (from 1,119 ± 98 mg/dL to $586 \pm 114 \text{ mg/dL}$) and total cholesterol (from $283 \pm 103 \text{ mg/dL}$ to $117 \pm 58 \text{ mg/dL}$) (Fig. 322 5D-F). Consistent with the above findings, increased TG concentrations in hAPOC3 Tq 323 mice accelerated AAA development during AnglI infusion (Fig 5G-L). After 324 administration of Anaptl3 ASO to hAPOC3 Tg mice, we recorded significant reductions 325 in AAA incidence, maximal aortic diameter, elastin degradation, and dissection, 326 comparable to the control mice (Fig 5G-L). qRT-PCR and ELISA analysis showed no

significant changes in the levels of mouse *Apoc3* and human *APOC3* (Fig 5M-P). There were no significant changes in the TG and TC metabolism-related genes in the liver, such as *Apoc2*, *Apoa5*, *Apoe*, *Apob*, *Mttp*, *Fasn*, *Srebp1c*, *Ldlr*, and *Pcsk9* (Supplementary Fig 8). *Angptl3* ASO administration did not significantly change body weight or systolic blood pressure (Fig 5Q-R). Overall, our findings demonstrate that administration of *Angptl3* ASO protected against hypertriglyceridemia accelerated AAA development in h*APOC3* Tg mice.

Angpt/3 ASO inhibits AAA development in Apoe-deficient mice.

ApoE-deficient mice have high levels of VLDL due to impaired clearance of chylomicron and VLDL. Compared with age and sex-matched C57BL/6J mice, Apoe-deficient mice show significantly increased plasma levels of TC and moderately increased TG levels when fed a standard rodent diet.³⁵ Similar to the observation in hAPOC3 Tg mice, administration of *Angptl3* ASO dramatically reduced hepatic *Angptl3* mRNA expression and the circulating levels of ANGPTL3 (Fig 6A-C). As expected, administration of the Anaptl3 ASO significantly decreased TG concentrations by 50%, NEFA by 31%, and slightly decreased TC concentrations by 8% in Apoe-deficient mice fed a standard rodent laboratory diet (Fig 6D-F). We also used size exclusion chromatography to separate lipoprotein classes and found decreased TG concentrations, mainly in VLDL and IDL (Fig 6I), while cholesterol concentrations were slightly reduced in VLDL and HDL (Fig 6J). Blood pressure measurements and body weight recordings revealed no significant difference between control ASO and Angptl3 ASO-administered mice (Fig. 6G, H). Consistent with the literature, AAA incidence in Apoe-deficient mice was 83% in the control group (Fig 6K, N). Anaptl3 ASO administration largely inhibited AAA development, as evidenced by significantly decreased AAA incidence and maximal aortic diameters (Fig 6N, O). Depletion of hepatic Anaptl3 had limited effects on the expression of genes involved in lipogenesis and cholesterol metabolism (Fig 6P). Taken together, these data demonstrated that lowering TG and NEFA concentrations by Angptl3 ASO inhibited AAA development in Apoe-deficient mice.

Discussion

327

328

329

330

331

332

333

334 335

336

337 338

339

340 341

342343

344 345

346

347

348

349 350

351

352

353

354

355 356 357

358

359

360 361

362

363

AAA screening programs have identified many asymptomatic AAA and effectively reduced aneurysm-related mortality. Thus, limiting aneurysm growth and reducing the risk of aneurysm rupture has become a key priority for the treatment of AAA.³⁶ Based on the genetic, proteomic, and metabolomic findings, we identify that increased TG concentrations accelerate AAA formation and rupture using three hypertriglyceridemia murine models. Of clinical relevance, we provide evidence that lowering TG and NEFA

concentrations by *Angptl3* ASO administration dramatically inhibited AAA development and rupture.

Mendelian Randomization (MR) using protein quantitative trait loci (pQTLs) as instrumental variables (IVs) can help infer causality and identify drug targets for complex diseases. By integrating pQTLs from ten large GWAS on circulating proteins, we updated the 'actionable' druggable target pool into an enlarged set of 2,698 proteins. Genetically determined APOA5 and LPL, two critical molecules regulating triglyceride metabolism, were negatively associated with AAA risk. In contrast, the variants related to APOC3 with increased TG concentrations were associated with increased AAA risk, underscoring the role of triglyceride metabolism in human AAA development, consistent with other genetic findings. The further explored the causal effects of metabolites on AAA risk using IVs from 233 NMR-measured circulating metabolites. The strong associations found in VLDL and its subfractions as well as free fatty acid concentrations, further highlighted the importance of TG metabolism in AAA. Collectively, these findings emphasize the significance of TG in AAA risk and provide potential candidates for AAA prevention and treatment.

According to the literature and our experience, young C57BL/6J mice, when fed a standard rodent laboratory diet, have low AAA incidence when infused with Angll. 26,37 Hyperlipidemia increases the AAA incidence during AnglI infusion in LdIr and Apoedeficient mice or C57BL/6J mice with an AAV expressing a gain-of-function mutant of PCSK9, in which *Ldlr*-deficient mice and PCSK9 overexpressing mice are fed a Western diet to augment hypercholesterolemia.²⁶ Compared with C57BL/6J mice, Ldlr or Apoedeficient mice have significantly increased TC and TG concentrations, which mainly distribute in VLDL fractions using size exclusion chromatography to separate lipoprotein classes, ³⁸ indicating that increased concentrations of large, TG-rich lipoproteins are associated with AAA formation. Our previous study demonstrated that AAA development is accelerated with modestly hypercholesterolemic conditions, but further elevation of cholesterol above a threshold level does not enhance AAA progression.³⁷ Here, we present that increased TG concentrations contribute to AAA development, dissection, and rupture in a TG-concentration-dependent manner using three hypertriglyceridemia mouse models. The moderately increased TG concentrations in *Apoa5* deficiency mice accelerated AAA development, dramatically increased TG concentrations in hAPOC3 transgenic mice caused AAA dissection, and severely high TG concentrations resulted in aortic rupture and death in inducible Lpl-deficient mice. We also evaluated the effects of increased TG concentrations on aneurysm growth in the elastase-induced AAA model. Previous studies have demonstrated that the aneurysm growth in the PPE model is independent of hypercholesterolemic conditions using C57BL/6J mice with

PCSK9 overexpression or *Apoe*-deficient mice.^{27,39} Using the PPE-induced AAA model, we demonstrated that increased TG concentrations aggravated AAA growth in both male and female *APOC3* Tg mice. Furthermore, clinical observation shows that plasma TG concentrations are higher in AAA patients than in controls.⁹ In a prospective epidemiological study (the British United Provident Association [BUPA] study), the risk of death from AAA rupture is strongly related to serum TG concentrations.¹⁰ Together, these findings pave the way for future studies of the role of triglyceride and related metabolites in AAA development.

403

404 405

406

407

408 409

410

411 412

413 414

415

416

417

418

419

420

421

422

423

424

425 426

427

428 429

430

431

432

433

434

435

436

437

438 439

440

441

Importantly, our study demonstrates that lowering TG and NEFA levels by administrating Angpt/3 ASO inhibits AAA development in both hAPOC3 transgenic mice and Apoedeficient mice. ApoC-III raises TG concentrations by inhibiting LPL activity, reducing hepatic uptake of TG-rich lipoproteins, and promoting VLDL secretion. ApoE acts as a critical ligand for the LDL receptor and the LDL receptor-related protein, facilitating the uptake of chylomicron and VLDL remnants into hepatocytes. Deficiency of ApoE causes elevated TG and TC levels. In both APOC3 transgenic mice and Apoe-deficient mice, triglycerides and cholesterol are mainly distributed in VLDL fractions. Administration of Anaptl3 ASO dramatically reduced TG levels in VLDL and IDL fractions, consistent with decreased TG concentrations in plasma, supporting the hypothesis that large-sized TGrich lipoproteins and related metabolites contribute to AAA progression and rupture. These findings also provide evidence that lowering TG-rich lipoproteins is a potential therapeutic strategy. ANGPTL8 and ANGPTL3 form a complex that markedly inhibits LPL activity. Similar to the effects of Angpt/3 ASO on AAA, Angplt8-deficiency or knockdown reduced AAA formation by lowering TG concentrations and suppressing the inflammatory response in *Apoe*-deficient mice. 40 Administration of fenofibrate also reduced the severity of experimental AAA in *Ldlr*- and *Apoe*-deficient mice. 41,42 However, fenofibrate did not significantly limit AAA growth in AAA patients in FAME-2 (Fenofibrate in the Management of Abdominal Aortic Aneurysm 2), a placebo-controlled clinical trial.⁴³ We should note that it may take an estimated five years for a small AAA with a diameter of 40–55 mm to reach 55 mm, the size threshold for intervention.³⁶ In the FAME-2 study, AAA diameters in the control group increased only about 1 mm after a 24-week observation period, making it hard to determine the effects of fenofibrate. Additionally, AAA diameters in the two groups began to diverge at the end of the evaluation, suggesting that a long-term clinical trial with a larger sample size is needed to carefully assess the effects of triglyceride-lowering on AAA growth and rupture.

AAA is characterized by pathological remodeling of the aortic ECM, including elastolysis and collagenolysis. LOX is a crucial enzyme involved in the cross-linking of collagen and elastin in the ECM to maintain the structural integrity of the aortic wall. Impairments

443 444

445

446

447 448

449

450

451

452 453

454

455

456 457

458

459 460

461 462

463 464

465

466

467

468

469

470 471

472

473

474

475 476

477

478

479

in LOX activity due to genetic mutations can lead to connective tissue disorders and promote aorta dissection.44 Lox-deficient mice exhibit severe defects in vascular development, leading to perinatal death from a ortic aneurysm. 31 β-Aminopropionitrile (BAPN) is a well-known inhibitor of LOX and has been used extensively in research to accelerate AAA formation and rupture. 45 LOX is initially synthesized as a preproprotein and secreted into the extracellular space, where the prolysyl oxidase is cleaved by proteases, including BMP-1, ADAMTS-2, and ADAMTS-14. Increased TG concentrations or the presence of palmitate dramatically blocked LOX maturation in aortas and HASMCs. Based on RNA-seq findings, BMP-1 and ADAMTS-2 are highly abundant in HASMC. PA downregulated the expression of BMP-1 and ADAMTS-2, causing decreased LOX maturation. Additionally, PA induces vascular SMC apoptosis, promotes inflammatory responses, enhances oxidative stress, and triggers proliferation and migration, contributing to the progression of vascular diseases such as atherosclerosis and hypertension.⁴⁶ In this study, we demonstrated that PA, potentially originating from plasma triglycerides, may contribute to AAA development by inhibiting LOX maturation. Lowering TG and NEFA by administration of *Anaptl3* ASO can inhibit AAA development, suggesting that managing triglyceride concentrations and related metabolites through lifestyle changes and pharmacotherapy may reduce the risk of AAA development.

Plasma TG concentrations include the content of various lipoprotein particles. Multiple genes, such as LPL, APOC3, APOC2, APOA5, and ANGPTL3, influence TG metabolism and regulate plasma TG concentrations. Among them, APOC3 and ANGPTL3 are targets for drug development because loss-of-function mutations in APOC3 and ANGPTL3 are associated with improved lipid profiles and reduced cardiovascular risk. Preclinical and clinical data have well documented that ApoC-III or ANGPTL3 inhibitors effectively reduce severe hypertriglyceridemia. These inhibitors include antisense nucleotides (ASO), 14,16,34 monoclonal antibodies (mAb), 47 small interfering RNA (siRNA), 48,49, and CRISPR-cas gene editing strategies. 50,51 Preclinical and clinical data have demonstrated that ANGPTL3 inhibitors are highly effective for treating severe hypertriglyceridemia by upregulating LPL activity and facilitating the hydrolysis and clearance of TG-rich lipoproteins. As hAPOC3 transgenic mice have very high APOC3 and TG concentrations, Angpt/3 ASO was administrated at 50 mg/kg/week in previous studies. 16 In this study, administration of an *Angptl3* ASO at a much lower dosage effectively reduced AAA development in hAPOC3 transgenic mice and Apoedeficient mice through reducing TG concentrations, especially TG concentrations in VLDL fractions. We observed that the administration of *Angpt/3* ASO mainly decreased plasma TG concentrations with a limited reduction in plasma TC concentrations, further

supporting the idea that managing TG-rich lipoprotein concentrations is a potential therapeutic strategy for treating AAA.

In summary, the present studies, combined with recent genetic, proteomic, and metabolomic findings, indicate that increased TG concentrations increase AAA risk. Individuals at higher genetic risk for AAA might benefit from targeted interventions. Understanding the association between triglyceride concentrations and AAA risk has important clinical implications. These findings prove that ASO administration targeting ANGPTL3 may become a therapy to reduce the risk of AAA. The present studies should stimulate further experimental and clinical investigations of the mechanisms and therapeutic strategies for AAA treatment via triglyceride-lowering therapies.

Funding

This study was partially supported by the National Institutes of Health grants HL166203 (Y.G.), HL165688 (Y.G. and A.S.), HL109946 and HL134569 (Y.E.C.), HL151524 (L.C.), HL153710 and HL138139 (J.Z.), HL172832 (G. Zhao), R35HL155649 (A.D.), UL1TR001998 (A.D.), R21 NS11191 (A.S.) and the American Heart Association Merit award 23MERIT1036341 (A.D.).

Disclosures

The authors have no competing interests.

Data availability

All genetic data used in this study were obtained from publicly available consortiums. The RNAseq original data generated during this study will be deposited in a publicly accessible database upon acceptance of the manuscript.

References

505

- Nordon, I.M., Hinchliffe, R.J., Loftus, I.M. & Thompson, M.M. Pathophysiology and epidemiology of abdominal aortic aneurysms. *Nat Rev Cardiol* **8**, 92-102 (2011).
- 509 2. United Kingdom Small Aneurysm Trial, P., *et al.* Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med* **346**, 1445-1452 (2002).
- 512 3. Soden, P.A., *et al.* Outcomes for symptomatic abdominal aortic aneurysms in the 513 American College of Surgeons National Surgical Quality Improvement Program. 514 *J Vasc Surg* **64**, 297-305 (2016).
- 515 4. Reimerink, J.J., van der Laan, M.J., Koelemay, M.J., Balm, R. & Legemate, D.A. Systematic review and meta-analysis of population-based mortality from ruptured abdominal aortic aneurysm. *Br J Surg* **100**, 1405-1413 (2013).
- 5. Golledge, J., Thanigaimani, S., Powell, J.T. & Tsao, P.S. Pathogenesis and management of abdominal aortic aneurysm. *Eur Heart J* **44**, 2682-2697 (2023).
- 520 6. Roychowdhury, T., *et al.* Genome-wide association meta-analysis identifies risk 521 loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. 522 *Nat Genet* **55**, 1831-1842 (2023).
- 523 7. Harrison, S.C., *et al.* Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. *JAMA Cardiol* **3**, 26-33 (2018).
- 525 8. Klarin, D., *et al.* Genetics of blood lipids among ~300,000 multi-ethnic 526 participants of the Million Veteran Program. *Nat Genet* **50**, 1514-1523 (2018).
- 527 9. Norrgard, O., Angquist, K.A. & Johnson, O. Familial aortic aneurysms: serum 528 concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)-529 cholesterol. *Br J Surg* **72**, 113-116 (1985).
- 530 10. Watt, H.C., *et al.* Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. *Int J Epidemiol* **27**, 949-952 (1998).
- 532 11. Subramanian, S. Hypertriglyceridemia: Pathophysiology, Role of Genetics,
 533 Consequences, and Treatment. in *Endotext* (eds. Feingold, K.R., *et al.*) (South

534 Dartmouth (MA), 2000).

- 535 12. Pennacchio, L.A., *et al.* An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* **294**, 169-173 (2001).
- 537 13. Breckenridge, W.C., Little, J.A., Steiner, G., Chow, A. & Poapst, M.

 Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. *N Engl J*Med **298**, 1265-1273 (1978).
- 540 14. Witztum, J.L., *et al.* Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med* **381**, 531-542 (2019).

- 542 15. Bergmark, B.A., *et al.* Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. *N Engl J Med* **390**, 1770-1780 (2024).
- 544 16. Graham, M.J., *et al.* Cardiovascular and Metabolic Effects of ANGPTL3 545 Antisense Oligonucleotides. *N Engl J Med* **377**, 222-232 (2017).
- 546 17. Rosenson, R.S., *et al.* Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. *N Engl J Med* (2024).
- 548 18. Burgess, S., *et al.* Using genetic association data to guide drug discovery and development: Review of methods and applications. *Am J Hum Genet* **110**, 195-550 214 (2023).
- 551 19. Gaziano, L., *et al.* Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. *Nat Med* **27**, 668-676 (2021).
- 553 20. Karjalainen, M.K., *et al.* Genome-wide characterization of circulating metabolic biomarkers. *Nature* **628**, 130-138 (2024).
- Ibrahim, M., Thanigaimani, S., Singh, T.P., Morris, D. & Golledge, J. Systematic
 review and Meta-Analysis of Mendelian randomisation analyses of Abdominal
 aortic aneurysms. *Int J Cardiol Heart Vasc* 35, 100836 (2021).
- 558 22. Raffort, J., *et al.* Diabetes and aortic aneurysm: current state of the art. *Cardiovasc Res* **114**, 1702-1713 (2018).
- Daugherty, A. & Cassis, L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. *Ann N Y Acad Sci* **892**, 108-118 (1999).
- 563 24. Daugherty, A., Manning, M.W. & Cassis, L.A. Angiotensin II promotes 564 atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin* 565 *Invest* **105**, 1605-1612 (2000).
- Lu, H., et al. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function
 Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in
 C57BL/6 Mice-Brief Report. Arterioscler Thromb Vasc Biol 36, 1753-1757 (2016).
- Sawada, H., Lu, H.S., Cassis, L.A. & Daugherty, A. Twenty Years of Studying
 Angll (Angiotensin II)-Induced Abdominal Aortic Pathologies in Mice: Continuing
 Questions and Challenges to Provide Insight Into the Human Disease.
 Arterioscler Thromb Vasc Biol 42, 277-288 (2022).
- 573 27. Mulorz, J., *et al.* Hyperlipidemia does not affect development of elastase-induced abdominal aortic aneurysm in mice. *Atherosclerosis* **311**, 73-83 (2020).
- 575 28. Golledge, J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. *Nat Rev Cardiol* **16**, 225-242 (2019).
- 577 29. Carta, G., Murru, E., Banni, S. & Manca, C. Palmitic Acid: Physiological Role, 578 Metabolism and Nutritional Implications. *Front Physiol* **8**, 902 (2017).
- 579 30. Staiculescu, M.C., Kim, J., Mecham, R.P. & Wagenseil, J.E. Mechanical behavior and matrisome gene expression in the aneurysm-prone thoracic aorta of

- 581 newborn lysyl oxidase knockout mice. *Am J Physiol Heart Circ Physiol* **313**, 582 H446-H456 (2017).
- 583 31. Lee, V.S., *et al.* Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. *Proc Natl Acad Sci U S A* **113**, 8759-8764 (2016).
- 586 32. Franklin, M.K., *et al.* beta-Aminopropionitrile Induces Distinct Pathologies in the 587 Ascending and Descending Thoracic Aortic Regions of Mice. *Arterioscler Thromb* 588 *Vasc Biol* **44**, 1555-1569 (2024).
- 589 33. Eguchi, K., *et al.* Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. *Cell Metab* **15**, 518-533 (2012).
- Bergmark, B.A., et al. Effect of Vupanorsen on Non-High-Density Lipoprotein
 Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol:
 TRANSLATE-TIMI 70. Circulation 145, 1377-1386 (2022).
- 594 35. Plump, A.S., *et al.* Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. *Cell* **71**, 343-353 (1992).
- 597 36. Ulug, P., Powell, J.T., Martinez, M.A., Ballard, D.J. & Filardo, G. Surgery for small asymptomatic abdominal aortic aneurysms. *Cochrane Database Syst Rev* **7**, CD001835 (2020).
- Liu, J., *et al.* Associations of ApoAl and ApoB-containing lipoproteins with AngIIinduced abdominal aortic aneurysms in mice. *Arterioscler Thromb Vasc Biol* **35**, 1826-1834 (2015).
- Ishibashi, S., Herz, J., Maeda, N., Goldstein, J.L. & Brown, M.S. The tworeceptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. *Proc Natl Acad Sci U S A* **91**, 4431-4435 (1994).
- 607 39. Ikezoe, T., *et al.* No Effect of Hypercholesterolemia on Elastase-Induced 608 Experimental Abdominal Aortic Aneurysm Progression. *Biomolecules* **11**(2021).
- 40. Yu, H., *et al.* ANGPTL8 deletion attenuates abdominal aortic aneurysm formation in ApoE-/- mice. *Clin Sci (Lond)* **137**, 979-993 (2023).
- Krishna, S.M., *et al.* Fenofibrate increases high-density lipoprotein and
 sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm
 progression in a mouse model. *Am J Pathol* 181, 706-718 (2012).
- Golledge, J., *et al.* Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. *Atherosclerosis* **210**, 51-56 (2010).
- 617 43. Pinchbeck, J.L., *et al.* Randomized Placebo-Controlled Trial Assessing the Effect 618 of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic

- Aneurysm: Outcomes From the FAME -2 Trial. *J Am Heart Assoc* **7**, e009866 (2018).
- 621 44. Guo, D.C., *et al.* LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. *Circ Res* **118**, 928-934 (2016).
- 623 45. Kanematsu, Y., *et al.* Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. *Hypertension* **55**, 1267-1274 (2010).
- Hu, Y., Fan, Y., Zhang, C. & Wang, C. Palmitic acid inhibits vascular smooth muscle cell switch to synthetic phenotype via upregulation of miR-22 expression. *Aging (Albany NY)* **14**, 8046-8060 (2022).
- 628 47. Gaudet, D., *et al.* Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. *Eur Heart J* **45**, 2422-2434 (2024).
- Watts, G.F., *et al.* RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. *Nat Med* **29**, 2216-2223 (2023).
- 633 49. Gaudet, D., *et al.* RNA Interference Therapy Targeting Apolipoprotein C-III in 634 Hypertriglyceridemia. *NEJM Evid* **2**, EVIDoa2200325 (2023).
- 50. Zha, Y., *et al.* CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits. *Lipids Health Dis* **20**, 180 (2021).
- 51. Zuo, Y., *et al.* Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. *Cell Biosci* **13**, 109 (2023).

Figures

640

641

656

657

Fig. 1: Mendelian Randomization identifies circulating proteins and metabolites

642 causally related to AAA risk.

- 643 A, Outline of the analyses performed. Two-sample Mendelian Randomization (MR)
- analyses were applied to determine the causal effects of circulating proteins, and
- 645 nuclear magnetic resonance (NMR) measured circulating metabolites on the risk of
- abdominal aortic aneurysm (AAA) using multiple data sources. **B**, Forest plot displaying
- the causal effects of 41 proteins identified through MR-Wald ratio analysis after
- Bonferroni correction. C, Classifications of NMR metabolites and the relative lipid
- compositions of the 14 lipoprotein subclasses (left). All 14 lipoprotein subclass particles
- are illustrated using the same size scale, with diameters based on mean values from
- 5,651 participants in the Northern Finland Birth Cohort 1966 (NFBC66). Note that the
- size of the LDL and HDL particles in the figure is multiplied by 1.5 and 2.0, respectively.
- The right side features a circular histplot of the MR results for 141 metabolites. Each
- bar's height represents the absolute effect size, while the color indicates the direction
- and P-value as determined by the MR inverse-variance weighted (IVW) method.

Fig. 2: Impaired LPL activity accelerates AAA development and aortic rupture.

- 658 **A**, Design of the AAA study in *Lpl*-deficient mice. Inducible global *Lpl*-deficient mice
- were generated by crossing Lpl floxed (Lpl^{f/f}) mice with β -actin driven tamoxifen-
- 660 inducible MerCreMer transgenic mice. Low cholesterol, Western diet feeding was
- initiated 2 weeks after the start of tamoxifen treatment. **B**, Aortic rupture incidence curve
- during 4 weeks of AnglI infusion. **C**, Aortic aneurysm incidence in $LpI^{f/f}$ (n=11) and $LpI^{f/f}$
- 663 (n=10) mice. **D**, Design of the AAA study in *Apoa5*-deficient mice. Mice were fed a
- standard rodent laboratory diet. After 4-week of AnglI infusion, aortas from surviving
- mice were harvested. **E**, Representative aorta of male WT (n = 14) and *Apoa5*-deficient
- (n = 15) mice after 4 weeks of AngII infusion. Plasma samples were collected on day 28
- and subjected individually to analytical chemistry to measure triglycerides (TG) and total
- 668 cholesterol (TC). **F-J**, The TG (**F**), TC (**G**), maximal aortic diameter (**H**), AAA incidence
- 669 (I), and systolic blood pressure (J) in male mice. K-O, TG (K), TC (L), maximal aortic
- diameter (\mathbf{M}), AAA incidence (\mathbf{N}), and systolic blood pressure (\mathbf{O}) in female WT (n = 10)
- and *Apoa5*-deficient (n = 8) mice in AnglI-induced AAA study. Data are presented as
- 672 circles and Mean ± SEM (**F-H**, **J -M**, **O**). Statistical analyses were conducted as follows:
- 673 Chi-Squared test for C, I, N; Mann-Whitney U test for F, M; Student's t-test for G, H, K,
- 674 L; Kruskal-Wallis test followed by Dunn's post hoc analysis for J; One-way ANOVA
- 675 followed by Sidak post hoc analysis for **O**. SBP, systolic blood pressure.

Fig. 3: Dramatically increased TG concentrations accelerate AAA development and rupture in hAPOC3 Tg mice.

676

677

695

696

701

678 A, Design of the AAA study in human APOC3 transgenic (hAPOC3 Tg) mice. Twelve- to 16-week-old hAPOC3 Tg mice (n of male = 15; n of female = 24) or WT littermates (n of 679 680 male = 17, n of female =21) were infused with AngII (1,000 ng/kg/min) for 4 weeks to 681 induce AAA. Systolic blood pressures were measured before and after AnglI infusion. 682 The mice were fed a standard rodent laboratory diet. After 4 weeks, aortas from 683 surviving mice were harvested. Plasma samples were collected on day 28 and 684 subjected individually to analytical chemistry. **B-D**, plasma triglycerides (TG) (**B**), total 685 cholesterol (TC) (C), and non-esterified fatty acids (D) in male mice. Representative 686 aortas of male WT and hAPOC3 Tg mice after 4 weeks of AnglI infusion (E). Maximal 687 aortic diameter (F), AAA incidence (G), dissection rate (H), and systolic blood pressure 688 (I) in male mice. J-Q, The TG (J), TC (K), non-esterified fatty acids (L), maximal aortic 689 diameter (M), AAA incidence (N), and dissection rate (O) in female WT and hAPOC3 Tg 690 mice after 4 weeks of AnglI infusion. Data are presented as circles and Mean ± SEM (B-691 **D**, **F**, **I-M**). Statistical analyses were conducted as follows: Mann-Whitney U test for **B**, 692 D, F, J, K; Student's t-test for C, L, M; Chi-Squared test for G, H, N, O; One-way 693 ANOVA followed by Sidak post hoc analysis for I. Scale bars: 1 mm in E. SBP, systolic 694 blood pressure; NEFA, non-esterified fatty acids.

Fig. 4: Palmitic acid inhibits LOX maturation in HASMCs and aortas.

697 A-F. Human aortic smooth muscle cells (HASMCs) were starved in OptiMEM-reduced 698 serum medium for 24 hours, followed by incubation with palmitic acid (250 µM; PA) or 699 vehicle (BSA) for another 24 hours. Total RNA was extracted for RNA sequencing or 700 qRT-PCR. A, Reactome pathway enrichment analysis of down-regulated genes in the PA group. **B**, Top 5 downregulated Reactome pathways identified from Gene Set 702 Enrichment Analysis (GSEA). C, Heatmap of gene expression levels in the collagen chain trimerization pathway. **D**, Heatmap of gene expression levels involved in elastic 703 704 fiber formation and maturation. qRT-PCR analysis of LOX (E) and BMP1, ADAMTS2, 705 and ADAMTS14 (F) (data from 4 independent experiments). G, I, HASMCs were 706 starved in OptiMEM for 24 hours, then incubated with PA (250 µM) or vehicle along with 707 TGF-β (10 ng/ml) or vehicle for another 24 hours. Total proteins were extracted for 708 Western blot analysis. G. Representative Western blot image of mature LOX and 709 premature form of LOX. I. Quantification analysis of mature LOX protein abundance 710 (data from 5 independent experiments). H, HASMCs were transfected with adenovirus 711 LacZ or LOX (30 MOI) for 2 hours in a growth medium, then starved in OptiMEM for 712 another 22 hours. Cells were incubated with PA (250 µM) or vehicle for an additional 24

- 713 hours. Total proteins were then extracted for Western blot analysis of mature and
- premature LOX. **J**, Eight-week-old male C57BL/6J mice were given saline, vehicle, or
- ethyl palmitate (600 mg/kg) for 5 consecutive days via intraperitoneal injection. On day
- 716 6, mice were euthanized, suprarenal abdominal aortas were isolated, and total protein
- 717 was extracted and analyzed by Western blot to detect mature LOX abundance in
- suprarenal abdominal aortas, with corresponding quantifications (n = 5/group). **K**,
- 719 Twelve- to 16-week-old hAPOC3 Tg mice and littermate control mice were infused with
- saline or AnglI (1,000 ng/kg/min) for 7 days. On day 8, mice were euthanized,
- suprarenal abdominal aortas were isolated, and total protein was extracted and
- analyzed by Western blot to detect mature LOX expression in suprarenal abdominal
- aortas, with corresponding quantifications (n = 3 or 4/genotyping/treatment). Data are
- presented as dots and Mean ± SEM (**E**, **F**, **I-K**). Statistical analyses were conducted as
- follows: Student's t-test for **E**, **F**; Mann-Whitney U test followed by Bonferroni correction
- for I; One-way ANOVA followed by Sidak post hoc analysis for J, K.

Fig. 5: Administration of *Angptl3* ASO prevents AAA formation in hAPOC3 Tg

729 **mice**.

727

- 730 **A**, Design of the *Angptl3* ASO study in human *APOC3* Tg mice. Twelve- to 16-week-old
- male hAPOC3 Tg mice were given one injection of Angpt/3 ASO (10 mg/kg) or
- scrambled ASO by subcutaneous administration. After 3 days, mice were infused with
- 733 Angll (1,000 ng/kg/min) for 25 days. Three more injections (3 mg/kg) were conducted
- on days 7, 14, and 21. A wild-type group was included, receiving injections of scramble
- ASO. At the end of the study, aortas, livers, and plasma were harvested. **B**, Relative
- abundance of *Angptl3* mRNA in livers of the three groups. **C-D**, Plasma ANGPTL3
- protein concentrations (C) and non-esterified fatty acids (D) at the endpoint. E to F,
- Plasma triglycerides (TG) (**E**) and total cholesterol (TC) (**F**) concentrations on days 0, 3,
- and 28. **G**, Representative aortic trees from the 3 groups. **H**, Representative H&E
- staining (left) and Verhoeff-Van Gieson (VVG) staining (right) of suprarenal abdominal
- aorta sections. I-L. Quantifications of AAA incidence (I), maximal aorta diameter (J).
- elastic fiber degradation score (**K**), and dissection rate (**L**) among the 3 groups. **M**,
- 743 Relative abundance of *Apoc3* in the liver. **N**, Plasma mouse-specific APOC3
- concentrations were measured by ELISA at the endpoint. **O**, Relative liver abundance of
- human APOC3. **P**, Plasma human APOC3 concentrations were determined by ELISA at
- the endpoint. **Q**, Body weight comparisons among the 3 groups before and at the end of
- the study. **R**, Systolic blood pressure comparisons among the 3 groups before and at
- 748 the end of the study. Data are presented as circles/dots and Mean ± SEM or Mean only.
- Statistical analyses were conducted as follows: One-way ANOVA followed by Sidak post

- hoc analysis for **B**, **C**, **D**, **E**, day 3 of **F**, **M**, **N**, **R**; Kruskal-Wallis test followed by Dunn's
- post hoc analysis for day 0 and 28 of **F, J, K, O, P, Q**; Chi-Squared test for **I, L**. Scale
- bars: 1 mm in **G**, 50 µm in **H**. SBP, systolic blood pressure; NEFA, non-esterified fatty
- acids; #, P < 0.005 of the comparison of Ctr and WT group. *, P < 0.005 of the
- 754 comparison of Ctr and ASO group.

Fig. 6: Administration of *Angptl3* ASO prevents AAA formation in *Apoe*-deficient

757 **mice.**

755

- 758 **A**, Design of the *Angptl3* ASO study in male *Apoe*-deficient mice. Ten-week-old male
- 759 Apoe-deficient mice were given a subcutaneous injection of Angpt/3 ASO (10 mg/kg; n =
- 760 13) or scrambled ASO (n = 12). After 3 days, mice were infused with AnglI (1,000
- ng/kg/min) for 25 days. Three more injections were administered on days 7, 14, and 21.
- At the end of the study, aortas, livers, and plasma were harvested. **B**, Relative
- abundance of *Angptl3* mRNA in the liver. **C-D**, Plasma ANGPTL3 protein concentrations
- 764 (**C**), and non-esterified fatty acids (**D**) at the endpoint. **E**, Plasma triglycerides (TG)
- levels on days 0, 3, and 28. **F**, Plasma total cholesterol (TC) concentrations on days 3
- and 28. **G**, Systolic blood pressure before and after AnglI infusion. **H**, Body weight
- 767 changes. TG (I) and cholesterol (J) concentrations of size exclusion chromatography
- fractionated plasma from animals (n = 4 in the control group, n = 4 in the Angptl3 ASO
- group) determined by enzymatic assays. Fractions 8 to 11 contained VLDL, fractions 12
- to 17 contained IDL and LDL, and fractions 22 to 25 contained HDL. **K**, Representative
- aortic images from the 2 groups. **N-O**, Quantification of AAA incidence (**N**) and maximal
- aortic diameter (**O**). **P**, Relative liver mRNA abundance of genes related to VLDL
- production (Apob, Mttp, Srebp1c, Scd, Fasn), TG lipolysis (Apoc2, Apoc3, Apoa5, Lpl),
- and TC regulation (*Pcsk9*, *Ldlr*, *Lrp1*). Data are presented as circles/dots and/or Mean ±
- SEM. Statistical analyses were conducted as follows: Student's t-test for **B**, **C**, day 0
- and 28 of **E**, day 28 of **F**; Mann-Whitney U test for **D**, day 3 of **E** and **F**, **O**; One-way
- ANOVA followed by Sidak post hoc analysis for G: Chi-Squared test for N: Student's t-
- test or Mann-Whitney U test for **P**. Scale bars: 1 mm in **K**. SBP, systolic blood pressure:
- 779 NEFA, non-esterified fatty acids.











